• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

描述接受玻璃体内抗血管内皮生长因子注射治疗的患者对侧眼新生血管性年龄相关性黄斑变性的进展情况。

Characterizing Progression to Neovascular AMD in Fellow Eyes of Patients Treated With Intravitreal Anti-VEGF Injections.

出版信息

Ophthalmic Surg Lasers Imaging Retina. 2021 Mar;52(3):123-128. doi: 10.3928/23258160-20210302-02. Epub 2021 Mar 1.

DOI:10.3928/23258160-20210302-02
PMID:34038686
Abstract

BACKGROUND AND OBJECTIVE

The purpose of this study was to assess the real-world incidence of conversion to bilateral neovascular age-related macular degeneration (nAMD) following treatment initiation of nAMD in the initial eye.

PATIENTS AND METHODS

This was a retrospective cohort of electronic health records from retinal centers across the United States (Vestrum Database) of all patients with unilateral nAMD treated with anti-vascular endothelial growth factor therapy.

RESULTS

A total of 22,553 patients with unilateral nAMD were included. Fellow eyes of 8,522 patients (38%) converted to nAMD. Among these, 2,639 (12%), 2,030 (9%), and 1,802 (8%) patients converted in Years 1, 2, and 3, respectively, after diagnosis in the first eye. Fellow eyes had better vision at conversion and 1 year following conversion.

CONCLUSIONS

The fellow eye should be monitored at regular intervals to detect signs of neovascularization. Fellow eyes presented with significantly better vision at diagnosis than the initial eye and maintained better visual acuity with less injections. .

摘要

背景与目的

本研究旨在评估在初始眼接受新生血管性年龄相关性黄斑变性(nAMD)治疗后,双侧 nAMD 实际转化率。

患者与方法

本研究为回顾性队列研究,分析了美国各地视网膜中心的电子健康记录(Vestrum 数据库)中所有接受抗血管内皮生长因子治疗的单侧 nAMD 患者。

结果

共纳入 22553 例单侧 nAMD 患者。8522 例患者(38%)的对侧眼发生 nAMD。其中,2639 例(12%)、2030 例(9%)和 1802 例(8%)患者分别在第 1、2 和 3 年诊断出第一只眼后发生了 nAMD。对侧眼在转归时和转归后 1 年的视力更好。

结论

应定期监测对侧眼,以发现新生血管化的迹象。与初始眼相比,对侧眼在诊断时视力明显更好,且注射次数更少,视力保持更好。

相似文献

1
Characterizing Progression to Neovascular AMD in Fellow Eyes of Patients Treated With Intravitreal Anti-VEGF Injections.描述接受玻璃体内抗血管内皮生长因子注射治疗的患者对侧眼新生血管性年龄相关性黄斑变性的进展情况。
Ophthalmic Surg Lasers Imaging Retina. 2021 Mar;52(3):123-128. doi: 10.3928/23258160-20210302-02. Epub 2021 Mar 1.
2
Fellow Eye Comparisons for 7-Year Outcomes in Ranibizumab-Treated AMD Subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study).AMD 患者接受雷珠单抗治疗的 7 年结局的眼间比较:来自 ANCHOR、MARINA 和 HORIZON 的研究(SEVEN-UP 研究)。
Ophthalmology. 2016 Jun;123(6):1269-77. doi: 10.1016/j.ophtha.2016.01.033. Epub 2016 Mar 18.
3
[Real-life results of anti-VEGF treatment in fellow eyes with nAMD].[抗VEGF治疗对患有湿性年龄相关性黄斑变性(nAMD)的对侧眼的实际治疗效果]
Ophthalmologe. 2022 Mar;119(3):272-279. doi: 10.1007/s00347-021-01473-7. Epub 2021 Aug 5.
4
Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes.比较新生血管性年龄相关性黄斑变性患眼与对侧非新生血管眼的黄斑萎缩演变。
Graefes Arch Clin Exp Ophthalmol. 2023 Dec;261(12):3425-3436. doi: 10.1007/s00417-023-06168-0. Epub 2023 Aug 11.
5
Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of 49 485 Eyes.新生血管性年龄相关性黄斑变性患者的视力结果和抗血管内皮生长因子治疗强度:49485 只眼的真实世界分析。
Ophthalmol Retina. 2020 Jan;4(1):19-30. doi: 10.1016/j.oret.2019.05.017. Epub 2019 May 25.
6
Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration.抗 VEGF 药物治疗新生血管性年龄相关性黄斑变性的 10 年真实世界临床经验。
Acta Ophthalmol. 2020 Mar;98(2):132-138. doi: 10.1111/aos.14183. Epub 2019 Jul 8.
7
Enhanced depth imaging of the choroid in patients with neovascular age-related macular degeneration treated with anti-VEGF therapy versus untreated patients.抗血管内皮生长因子治疗与未治疗的新生血管性年龄相关性黄斑变性患者脉络膜的增强深度成像。
Graefes Arch Clin Exp Ophthalmol. 2013 Jun;251(6):1483-8. doi: 10.1007/s00417-012-2199-x. Epub 2012 Nov 17.
8
Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study.血管内皮生长因子抑制剂治疗新生血管性年龄相关性黄斑变性的眼内黄斑萎缩发生率和进展:MANEX 研究四年结果。
Ophthalmology. 2020 Dec;127(12):1663-1673. doi: 10.1016/j.ophtha.2020.06.019. Epub 2020 Jun 13.
9
Incidence and risk factors for neovascular age-related macular degeneration in the fellow eye.对侧眼中新生血管性年龄相关性黄斑变性的发病率及危险因素
Graefes Arch Clin Exp Ophthalmol. 2018 Nov;256(11):2061-2068. doi: 10.1007/s00417-018-4100-z. Epub 2018 Aug 10.
10
Outcomes of Anti-Vascular Endothelial Growth Factor Treatment for Choroidal Neovascularization in Fellow Eyes of Previously Treated Patients With Neovascular Age-Related Macular Degeneration.抗血管内皮生长因子治疗对先前接受治疗的新生血管性年龄相关性黄斑变性患者对侧眼脉络膜新生血管的疗效。
JAMA Ophthalmol. 2018 Jul 1;136(7):820-823. doi: 10.1001/jamaophthalmol.2018.1534.

引用本文的文献

1
Prevention Surpasses Treatment: 5-year Follow-Up, Cost-Utility, and Cost-Benefit of Zeaxanthin Therapy for Neovascular Age-Related Macular Degeneration.预防优于治疗:叶黄素治疗新生血管性年龄相关性黄斑变性的5年随访、成本效益和成本效益分析
Ophthalmol Ther. 2023 Oct;12(5):2583-2608. doi: 10.1007/s40123-023-00742-9. Epub 2023 Jul 10.
2
Consequences of Real-World Surveillance of Fellow Eyes in Neovascular Age-Related Macular Degeneration.新生血管性年龄相关性黄斑变性对健眼进行真实世界监测的后果
Life (Basel). 2023 Jan 31;13(2):385. doi: 10.3390/life13020385.
3
Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects.
布罗鲁单抗治疗新生血管性年龄相关性黄斑变性和糖尿病性黄斑水肿:眼科和糖尿病学治疗方面
Ophthalmol Ther. 2023 Apr;12(2):639-655. doi: 10.1007/s40123-023-00647-7. Epub 2023 Jan 12.
4
Age-Related Macular Degeneration Masquerade: A Review of Pentosan Polysulfate Maculopathy and Implications for Clinical Practice.年龄相关性黄斑变性伪装:戊聚糖多硫酸酯黄斑病变的综述及对临床实践的影响。
Asia Pac J Ophthalmol (Phila). 2022;11(2):100-110. doi: 10.1097/APO.0000000000000504.